Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin

Genady Kostenich*, Nurit Livnah, Thomas A. Bonasera, Tamar Yechezkel, Yosef Salitra, Pninit Litman, Sol Kimel, Arie Orenstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Early, accurate detection of small-cell lung cancer (SCLC), before it becomes systemic, is essential for successful treatment. Fluorescence-based imaging provides safe, sensitive detection of malignancies. Targeted delivery of fluorophores increases sensitivity of endoscopic imaging. We synthesized novel somatostatin analogs, based on backbone cyclic peptides, and conjugated them with fluorescent agents. Nineteen conjugates differing in core peptide, length of alkyl linker and fluorescence moiety (rhodamine and fluorescein) were tested in vitro, using a receptor binding assay, and nine of the more promising conjugates were tested in vivo by fiber-optic spectrofluorimetry and quantitative spectral imaging, on an H69 human SCLC tumor mouse xenograft model. The lead compound showed exceptional tumor/normal tissue ratios, ranging from 9 to 90, and has potential for targeting SCLC overexpressing somatostatin receptors.

Original languageEnglish
Pages (from-to)319-328
Number of pages10
JournalLung Cancer
Issue number3
StatePublished - Dec 2005
Externally publishedYes


  • Fluorescence imaging
  • Somatostatin conjugates
  • Tumor targeting


Dive into the research topics of 'Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin'. Together they form a unique fingerprint.

Cite this